问道者 | 杜一用 由于电子商务和新技术给传统服装零售带来的冲击，九牧王从2014年开始尝试"实业+投资"，希望通过上下游相关产业投资助推服装主业发展，或者通过跨 界投资探索第二条增长曲线。 九牧王不是服装行业跨界投资的第一个吃螃蟹者。雅戈尔1992年就跨界房地产，2000年后又进军股权投资，把服装、地产和金融投资确定为"三驾马车"。 雅戈尔的跨界投资称得上传统服装零售行业的榜样。董事长李如成曾经公开表示，"雅戈尔投资房地产和金融赚的钱，做30年服装都赚不到。"从2001-2022 年获得的投资收益总共是将近470亿元，雅戈尔现在的市值也不过337亿元。 李如成2019年宣布"聚焦时尚主业"。现在回头去看，雅戈尔对跨界投资时机的把握相当精准，进入时房地产牛市刚启动，退出时恰逢巅峰，进退自如让雅戈 尔赚得盆盈钵满。 "男装第一股"雅戈尔收获41亿元投资回报时，"男裤专家"九牧王却因为跨界投资问题收到了上交所的问询函。由于最近三年跨界投资导致财富不断缩 水，"男裤专家"已决心戒掉跨界投资。 上交所的问询函让外界知道了"男裤专家"的家底。到2024年底，九牧王总资产57亿元，投资账面价值22.7亿元，在总资产中占比 ...

文章核心观点 - 全球生物科技公司Alvotech与全球制药公司Advanz Pharma达成AVT10（Cimzia®生物类似药候选产品）的供应和商业化协议，双方此前已有超十项生物类似药候选产品合作，预计2025年第四季度在欧洲推出首批生物类似药 [1][4] 合作协议情况 - Alvotech和Advanz Pharma达成AVT10（Cimzia®生物类似药候选产品）的供应和商业化协议 [1] - 双方此前已就超十项生物类似药候选产品达成合作协议，预计2025年第四季度在欧洲推出首批生物类似药 [4] 各方表态 - Alvotech董事长兼首席执行官Róbert Wessman表示该生物类似药候选产品是全球唯一正在开发的参照Cimzia®的产品，很高兴将其加入与Advanz Pharma不断扩大的商业合作中 [2] - Advanz Pharma首席执行官Steffen Wagner称该协议进一步加强了与Alvotech的战略伙伴关系，支持其为欧洲患者提供更多优质生物制剂的目标，Cimzia®生物类似药是其生物类似药管线的宝贵补充 [3] 产品背景 - Cimzia®（培化舍珠单抗）是一种TNF - α抑制剂，用于治疗多种炎症性疾病，2024年全球销售额达23亿美元 [3] 公司介绍 Alvotech - 由Robert Wessman创立，专注于为全球患者开发和生产生物类似药，旨在成为生物类似药领域的全球领导者，目前管线包括八个已披露的生物类似药候选产品，用于治疗自身免疫性疾病、眼部疾病等 [6] - 已与多家公司建立战略商业合作伙伴网络，覆盖美国、欧洲、日本、中国等市场，每个合作伙伴关系涵盖特定产品和地区 [6] Advanz Pharma - 总部位于英国伦敦，是一家全球制药公司，致力于改善患者生活，在全球90多个国家有商业销售，在20多个国家有直接商业存在，产品组合和管线包括创新药物、生物类似药、专科仿制药和原研品牌药 [7] - 产品覆盖肝病学、风湿病学等多个治疗领域，目标是成为欧洲、加拿大和澳大利亚专科、医院和罕见病药物商业化的首选合作伙伴 [7][8]

公司业务表现 - 安全访问服务边缘(SASE)业务是公司增长最快的业务 第三财季年度经常性收入(ARR)同比增长36% 是整体市场增速的两倍以上 [1] - Prisma Access Browser贡献了Prisma Access席位销售的三分之一 自收购Talon以来已售出300万许可证席位 较去年增长超10倍 [2] - 公司目前拥有约6000家SASE客户 同比增长22% 其中第三财季新增客户中40%为全新客户 [3] 产品战略 - Prisma Access Browser旨在保护浏览器环境 提供实时可见性和原生控制 保护敏感数据 [4] - 随着人工智能推动更多应用和数据上云 浏览器可能成为新的工作界面 Prisma Access Browser将成为公司SASE战略重要组成部分 [4] 竞争格局 - Zscaler通过ZIA和ZPA平台提供云原生安全访问 客户正用其零信任架构替代传统VPN [5] - Fortinet的FortiSASE平台推动快速增长 2025年第一季度统一SASE账单同比增长18% 占业务的25% [6] - Fortinet提供主权SASE解决方案 满足大型企业和服务提供商对数据本地化控制的需求 [6] 财务表现 - 公司股价年初至今上涨8.9% 低于安全行业20.2%的涨幅 [7] - 公司远期市销率为12.69倍 低于行业平均的14.52倍 [11] - 2025财年和2026财年盈利预期分别同比增长15.14%和11.19% 过去30天预期被上调 [14] 盈利预期趋势 - 当前季度(2025年7月)每股收益预期为0.88美元 与7天前持平 较30天前的0.86美元有所上调 [15] - 2025财年每股收益预期为3.27美元 与7天前持平 较30天前的3.22美元有所上调 [15] - 2026财年每股收益预期为3.64美元 与7天前持平 较30天前的3.61美元有所上调 [15]

Dogwood Therapeutics (DWTX) Conference June 11, 2025 09:15 AM ET Speaker0 Of our June 2025 SmallCap Conference. I'm Alex Antman, and I serve as an equity research analyst here at Sidoti and Company. Today, we're pleased to be in conversation with CEO and Chairman, Greg Duncan, of Dogwood Therapeutics, ticker DWTX. During the presentation, please feel welcome to submit questions using the Zoom Q and A interface at the bottom of your screen. After the presentation, we'll open to your questions. And with that, ...

Zscaler, Inc. (NASDAQ:ZS) Bank of America 2025 Global Technology Conference June 5, 2025 10:50 AM ET Company Participants Jagtar Singh Chaudhry - Co-Founder, CEO & Chairman of the Board Conference Call Participants Unidentified Analyst So I'm happy to host today for keynote, Jay Chaudhry we -- here we go. [indiscernible] you should learn from her also. So as I start with all our companies, I kind of discuss what investors are asking us about, just to set the framework for the discussion, I'll do it very qui ...

Zscaler (ZS) 2025 Conference June 05, 2025 10:50 AM ET Speaker0 So I'm happy to host today for keynote Jay Chondri. Here we go. Tomer, you should learn from her also. So as I start with Speaker1 all our Speaker0 companies, I kind of discuss what investors are asking us about just to set the framework for the discussion. I'll do it very quick. SASE remains an extremely hot space with very fast growth for most companies. There are new entrants though and the question is two things. Number one, how do you resp ...

Alvotech (ALVO) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 All righty. Good morning, and welcome to Jefferies Global Healthcare Conference. My name is Matthew Pakora with the Jefferies Healthcare Investment Banking team, and it's my great pleasure to introduce you to Doctor. Balaji Prasad, the Chief Strategy Officer. He will get us started here today. Speaker1 Thank you, Matthew. Good morning, everyone. My name is Balaji Prasad, the Chief Strategy Officer at Talvotech. It's my pleasure to present th ...

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane Biopharma AB (“Xbrane”), with the acqusition of the R&D organization of Xbrane in Sweden and biosimilar candidate to Cimzia® (certolizumab pegol). All regulatory conditions have been fulfilled. The transaction, which was announced on March 20, 2025, and approved by Xbrane’s Extraordinary General Meeting on April ...

Zscaler (ZS) Update / Briefing June 03, 2025 02:30 PM ET Speaker0 everyone. Apologize for the delay here. I would like to welcome you to Investor Relations Innovation Briefing at Zenith Live. We get started, please take moment to look at our safe harbor statements. Let's quickly go over the agenda after this. So we'll start off with some comments from Jay talking about the scale expansion. Jay, we'll have Adam will double into our SecOps strategy. After that, have special guest, Brian Byer, who is founder a ...

Zscaler (ZS) reported third-quarter fiscal 2025 non-GAAP earnings of 84 cents per share, which beat the Zacks Consensus Estimate by 12%. Moreover, the bottom line increased 18.3% year over year, driven by higher revenues and efficient cost management.ZS’ earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 18.7%.Zscaler’s third-quarter fiscal 2025 revenues of $678 million beat the Zacks Consensus Estimate by 1.8% and exceeded management’s guidance of $ ...